Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:54 AM
Ignite Modification Date:
2025-12-25 @ 2:54 AM
NCT ID:
NCT01041833
Eligibility Criteria:
Inclusion Criteria:
* Patients with advanced NSCLC (stages III B or IV according to the Tumor node metastasis \[TNM\] classification) who receive paclitaxel 175 mg/m2- and cisplatin-based palliative therapy every 3 weeks during 4 cycles,
* General status with a Karnofsky score of ≥70%,
* Eastern Cooperative Oncology Group (ECOG) ≤ 2,
* Hepatic and hematic cytology tests within normal ranges,
* Creatinine purification \> 75 ml per min,
* Those who accepted to participate in the study, and who signed the letter of informed consent.
Exclusion Criteria:
* Patients with comorbidity with another type of cancer who refuse to enter the protocol,
* Patients who require reduction of the chemotherapy dose due to alterations in their laboratory examinations,
* Patients with a poor general health state
* Absence of histological diagnosis, and
* Previous treatment with chemotherapy.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT01041833
Study Brief:
Protocol Section:
NCT01041833